Immuron licenses Travelan in China region
Immuron (ASX:IMC) has signed an agreement with a Chinese distributor to sell its Travelan OTC preventative treatment for traveller’s diarrhoea in China, Hong Kong and Macau.
Linker Holdings has negotiated the exclusive rights to market, sell and distribute Travelan in the region as a functional food and dietary supplement.
The agreement is contingent on Linker securing regulatory approval from the Chinese Food and Drug Administration.
Immuron said Linker has agreed to comply with annual minimum purchase obligations, and even these obligations represent a significant increase in Travelan sales figures, to the extent that it’s measurable in multiples of current volumes.
Immuron chairman Dr Roger Aston said Travelan is currently available in Australia and Canada, but the Chinese market has the potential to eclipse both markets combined in terms of demand.
“China is a large and increasingly wealthy market, in which gut and liver health are important concerns,” he said. “Additionally, the South East Asian cultures’ predisposition to, and appreciation of, the benefits of colostrum strongly positions Travelan in this market.”
Colostrum is the first milk produced by a pregnant mammal - it is naturally rich in antibodies. Immuron derives Travelan from cows that have been immunised with a proprietary vaccine against enterotoxigenic escherichia coli (ETEC).
Immuron (ASX:IMC) shares were trading 12.2% higher at $0.23 as of around 1 pm on Tuesday.
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...
AI-driven manufacturing: lessons from the life sciences industry
The use of artificial intelligence for batch monitoring and digital twin development is...
